On August 8 2023, THORNE HEALTHTECH ($NASDAQ:THRN) announced results for the second quarter of FY2023 (ending June 30 2023), with total revenue reaching USD 72.7 million, a considerable increase of 29.7% compared to the same period in the previous year. Furthermore, their net income increased by 179.6% to USD 4.4 million.
Analysis – Thorne Healthtech Intrinsic Value Calculator
GoodWhale has conducted an analysis of THORNE HEALTHTECH‘s financials and determined the fair value of THORNE HEALTHTECH share to be around $6.2. This calculation was done using our proprietary Valuation Line. Despite this fair value, the current market value of THORNE HEALTHTECH stock is being traded at $5.8, which is undervalued by 6.7%. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Thorne Healthtech. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Thorne Healthtech. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Thorne Healthtech. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Thorne Healthtech are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The health technology industry is a highly competitive market. Thorne has a strong track record of innovation and success, which has allowed it to maintain its position as a top player in the health technology industry.
Vitana-X Inc is a company that specializes in the development and sale of vitamins and supplements. The company has a market cap of 413.71k as of 2022 and a return on equity of 270.71%. Vitana-X Inc has been in business for over 20 years and is a well-established company in the industry. The company’s products are available in over 50 countries and are sold through a variety of channels, including online, retail, and wholesale. Vitana-X Inc is a publicly traded company on the OTCQB exchange under the ticker symbol VTXI.
The company’s market cap is 30.57B as of 2022. The company’s ROE is 11.34%. The company is involved in the manufacture and sale of health products.
– Wellnex Life Ltd ($ASX:WNX)
Wellnex Life Ltd is a biotechnology company that focuses on the development and commercialization of products for the treatment of osteoporosis and other bone-related diseases. The company has a market cap of 25.9M as of 2022 and a Return on Equity of -62.84%. Wellnex Life Ltd is headquartered in Vancouver, Canada.
Investors are likely to have mixed views of THORNE HEALTHTECH after their latest earnings report. Although the company reported a 29.7% increase in total revenue, from USD 72.7 million to USD 4.4 million, and a 179.6% increase in net income, the stock price declined the same day. This suggests that investors are perhaps expecting more from the company, given its high growth potential and long-term outlook. Analysts may now focus on whether THORNE HEALTHTECH can sustain its impressive growth and deliver consistent returns in the future.